The most comprehensive
neurotech company database

Abbott's neuromodulation division offers spinal cord stimulation, deep brain stimulation, and dorsal root ganglion therapies through products like the Proclaim DRG Neurostimulator and Infinity DBS system. Their BurstDR stimulation technology has been clinically shown to provide superior chronic pain relief compared to traditional tonic stimulation.

Acadia Pharmaceuticals is a biopharmaceutical company commercializing Nuplazid (pimavanserin), the first FDA-approved drug specifically for hallucinations and delusions associated with Parkinson's disease psychosis. They are also developing treatments for Alzheimer's disease psychosis and Rett syndrome.

Acer Therapeutics is a specialty pharmaceutical company focused on rare neurological and metabolic diseases, developing EDSIVOTM (sodium phenylbutyrate) for urea cycle disorders and other CNS conditions.

Advanced Brain Monitoring develops wireless EEG systems and sleep monitoring technology for research and clinical applications, including the B-Alert X-Series wearable EEG headsets and the Sleep Profiler device. Their tools are used in fatigue monitoring, cognitive workload assessment, and sleep staging.

Praxis Precision Medicine is developing genetically targeted therapies for epilepsy and essential tremor, including PRAX-628 and PRAX-944, precision ion channel modulators matched to specific genetic variants.

Aleva Neurotherapeutics is a Swiss medical device company developing directional deep brain stimulation leads for Parkinson's disease and other movement disorders. Their directSTIM technology enables highly targeted stimulation to maximize therapeutic benefit while minimizing side effects.

Canadian clinical-stage drug development company repurposing DMT as a stroke recovery treatment and exploring psychedelic compounds for neurological indications. Their AP-188 program targets neuroplasticity following ischemic stroke.

Alto Neuroscience uses EEG-based biomarkers and AI to match patients with psychiatric treatments most likely to work for their unique neurobiology, tackling the trial-and-error problem in antidepressant prescribing. Their precision psychiatry platform has demonstrated the ability to predict antidepressant response before treatment begins using neural signatures.

Canadian psychedelic company developing psilocybin microdosing protocols and digital therapeutics platforms to support mental health and cognitive performance. Their integrated approach combines pharmacology with behavioral health monitoring.

Arctop has developed a neural decoding platform that translates raw EEG signals from any compatible headset into standardized cognitive and emotional metrics via a cloud API. Their technology enables third-party applications to integrate personalized brain-adaptive experiences without custom hardware.

atai Life Sciences is a publicly listed biotech platform company building a portfolio of clinical-stage mental health companies developing psychedelic and non-psychedelic treatments for depression, PTSD, anxiety, and addiction. Their subsidiaries include programs using psilocybin, DMT, MDMA, and novel compounds.

Digital therapeutics company developing VR-enhanced psychedelic integration tools that support the therapeutic process before and after psychedelic medicine sessions. Their immersive environments are designed to maximize neuroplasticity windows post-treatment.

UK and European psychedelic medicine company developing ketamine-assisted psychotherapy treatments for addiction, particularly alcohol use disorder. They operate clinics and conduct Phase II/III clinical trials across Europe.

Awakn Life Sciences is a biotech company researching and developing ketamine and MDMA-based treatments for addiction disorders including alcohol use disorder, with clinical operations at their own therapy clinics in the UK. Their AWAKN-002 ketamine-assisted therapy program has completed Phase 2 clinical data for alcohol addiction.

Axsome Therapeutics is a commercial-stage biopharmaceutical company developing novel therapies for CNS disorders, with FDA-approved products including Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness. Their pipeline spans depression, Alzheimer's agitation, migraine, and narcolepsy.

Battelle's neurotechnology division pioneered NeuroLife, the first BCI system to reconnect a paralyzed person's brain to their muscles to restore hand movement using neural bypass technology. They continue to develop implantable and non-invasive BCI solutions under government and private research contracts.

Beacon Biosignals applies machine learning to EEG data to deliver scalable neural biomarkers for clinical trials and neurology applications. Their Dreem headband and cloud analytics platform help pharma companies measure brain activity endpoints at scale.

UK-based scientific research foundation pioneering psychedelic science and drug policy reform since 1998, collaborating with leading universities on psilocybin, LSD, and cannabis research. They bridge academic research with policy advocacy globally.

Beckley Psytech is a UK-based clinical-stage company developing short-duration psychedelic therapies, with a lead program using intranasal psilocybin (BPL-003) for treatment-resistant depression intended to reduce session time versus oral formulations. They are part of the Beckley Foundation's broader mission to advance psychedelic science.

Clinical-stage biotech developing subcutaneous ketamine formulations and wearable delivery devices for psychiatric treatment outside traditional clinic settings. Their approach aims to make ketamine therapy more accessible and scalable.

Big Health creates prescription digital therapeutics for mental health, including Sleepio for insomnia and Daylight for anxiety, both backed by clinical evidence. Their products are available through employer benefits and health plan coverage.

BioElectronics Corp manufactures wearable, disposable electroceutical patches using pulsed shortwave therapy to treat chronic and post-surgical pain without systemic drug side effects.

Argentinian psychedelic biotech company developing ayahuasca-derived DMT compounds and neural restoration therapies targeting addiction and neurodegenerative conditions. They leverage Latin America's rich ethnobotanical heritage in their drug discovery pipeline.

Bioness develops implantable and external neurostimulation devices for the rehabilitation of patients with neurological conditions such as stroke, multiple sclerosis, and traumatic brain injury. Their StimRouter peripheral nerve stimulator and NESS L300 foot drop system help patients restore functional movement and manage chronic pain.

BioXcel Therapeutics is developing BXCL501, a sublingual film formulation of dexmedetomidine for acute agitation in bipolar disorder and schizophrenia, leveraging AI-driven drug repurposing.

Blackfynn built a cloud-based data management and analytics platform for neuroscience research, enabling teams to store, process, and visualize large-scale neural datasets. The company was acquired by the University of Pennsylvania and spun into the SPARC Data and Connectivity platform.

BlackRock Neurotech manufactures implantable neural interfaces and research tools, including the Utah Array, which has been used in more human BCI implants than any other device in history. They serve both clinical and neuroscience research markets.

Boston Scientific's neuromodulation portfolio spans spinal cord stimulation, deep brain stimulation, and sacral neuromodulation for pain, movement disorders, and pelvic conditions. Their Vercise Genus DBS system and WaveWriter Alpha SCS platform represent the company's latest advances in closed-loop, personalized neural therapy.

BrainTrain develops computerized cognitive rehabilitation and neurofeedback software used by neuropsychologists and rehabilitation specialists worldwide. Their Captain's Log and SmartMind systems address attention, memory, and executive function deficits.

BrainBit produces a compact, wireless EEG headband with dry electrodes designed for consumer neurofeedback, cognitive monitoring, and developer experimentation. Their SDK and cloud platform enable third-party apps for focus training, meditation, and mental workload assessment.

BrainCare is a UK medtech company developing a non-invasive wearable device for continuous intracranial pressure monitoring using photoplethysmography signals. Their technology targets brain injury management and neurological monitoring in clinical settings.

BrainCo develops EEG-based brain-computer interface technology for prosthetics, education, and performance optimization, with their Focus edu device used in classrooms to monitor student attention. Their BrainRobotics prosthetic hand uses neural signals to enable intuitive motor control for amputees.

Neurolief is an Israeli medical device company developing the Relivion system, a multi-channel non-invasive transcranial and extracranial neurostimulation device for acute migraine treatment and prevention.

BrainsWay develops Deep TMS (dTMS) systems using patented H-Coil technology that stimulates deeper and broader brain regions than conventional TMS, with FDA clearances for major depression, OCD, and smoking cessation. Their non-invasive devices are deployed in psychiatric clinics across dozens of countries.

Bright Minds Biosciences designs next-generation serotonergic compounds targeting specific 5-HT receptor subtypes to treat epilepsy, PTSD, and addiction with reduced side effects. Their platform leverages computational drug design to create highly selective psychedelic-inspired molecules.

Brightside Health is a virtual mental health platform that combines therapy, psychiatry, and crisis support to treat depression and anxiety with clinically validated outcomes. Their proprietary Brightside Precision Treatment methodology adapts care to each patient's specific symptom profile and history.

Cambridge Cognition is a UK-based company providing digital cognitive assessment tools (CANTAB) used in clinical trials and brain health research worldwide. Their validated neuropsychological tests are trusted by pharmaceutical companies and academic institutions.

Emerging psychedelic biotech developing novel ibogaine-derived compounds for addiction treatment and neurological repair without the cardiac risks of ibogaine itself. Their pipeline targets opioid use disorder and traumatic brain injury.

Cerebral is a digital mental health company offering online access to licensed therapists, psychiatric prescribers, and care counselors for conditions including depression, anxiety, ADHD, and insomnia. Their subscription-based telehealth model has served millions of patients across the United States.

Athira Pharma is a clinical-stage biopharmaceutical company developing ATH-1017, a small molecule hepatocyte growth factor pathway activator aimed at restoring neuronal health in Alzheimer's disease.

Tonix Pharmaceuticals is a CNS-focused biopharmaceutical company developing Tonmya (TNX-102 SL), a sublingual cyclobenzaprine formulation for fibromyalgia and post-traumatic stress disorder.

Cerevel Therapeutics was a clinical-stage neuroscience company developing selective receptor-targeted therapies for schizophrenia, Parkinson's disease, and epilepsy, best known for emraclidine, a muscarinic receptor agonist for schizophrenia. Cerevel was acquired by AbbVie in 2024 for approximately $8.7 billion.

Ceribell has developed a rapid-deployment EEG system with an AI-powered brain seizure monitor for detecting non-convulsive seizures in ICU and emergency settings. Their point-of-care Clarity EEG system enables nurses to apply and interpret EEG results within minutes without a neurologist at the bedside.

Clinical-stage company developing psilocybin-based treatments for obsessive-compulsive disorder, eating disorders, and other hard-to-treat psychiatric conditions. They focus on indication-specific treatment protocols backed by rigorous clinical evidence.

Clerkenwell Health is a UK-based clinical research organization specializing in psychedelic medicine trials, offering full-service CRO capabilities for sponsors conducting psychedelic-assisted therapy studies. They operate dedicated trial sites across the UK.

UK-based psychedelic drug development company advancing novel ketamine and esketamine analogs for treatment-resistant depression and other psychiatric conditions. They focus on improving upon existing approved psychedelic medicines with next-generation compounds.

Cognition Therapeutics is developing CT1812, a small molecule sigma-2 receptor complex antagonist designed to displace toxic amyloid beta oligomers from synapses to treat Alzheimer's disease and dementia with Lewy bodies.

Cognito Therapeutics is developing non-invasive sensory stimulation therapies using 40Hz gamma frequency light and sound to target the neurological mechanisms underlying Alzheimer's disease. Their OVERTURE Phase 3 clinical trial is evaluating the Cognito Therapy System for slowing cognitive and functional decline in mild-to-moderate Alzheimer's patients.

Cogstate develops computerized cognitive assessments used in clinical trials for Alzheimer's disease, sports concussion, and neurological disorders. Their tests are scientifically validated and integrated into major pharmaceutical research programs globally.

Compumedics is an Australian publicly listed company that designs and manufactures sleep diagnostic and monitoring systems, EEG equipment, and transcranial Doppler ultrasound devices for clinical and research use. Their Grael and Somté product families are widely deployed in hospital sleep labs worldwide.

Cortec Neuro designs fully implantable neural interfaces and electrode arrays for both research and clinical applications. Their systems support long-term chronic recording and stimulation in freely moving subjects.

Cortivision is developing a non-invasive visual cortex stimulation device for the restoration of partial vision in people with visual impairment due to retinal and optic nerve disease. Their TMS-based neuromodulation approach targets the visual cortex to augment remaining visual function.

Cybin is a clinical-stage biopharmaceutical company developing proprietary psychedelic-based therapeutics, with lead programs targeting major depressive disorder using deuterated psilocybin analogs engineered for improved pharmacokinetics. Their CYB003 and CYB004 molecules are designed to provide more predictable and shorter therapeutic sessions.

Drug discovery company developing non-hallucinogenic psychoplastogenic compounds that promote neural plasticity similar to psychedelics without the perceptual effects. Their TrkB-targeting molecules aim to treat depression, addiction, and neurological disorders.

Dreem developed a consumer-grade EEG headband and companion app that monitors sleep stages in real time and uses bone-conduction audio stimulation to enhance deep sleep quality through neurofeedback. After being acquired by Beacon Biosignals, the Dreem technology continues to power sleep research platforms.

EEG Info, led by neurofeedback pioneer Siegfried Othmer, provides neurofeedback training systems, clinician education, and clinical protocols for treating ADHD, anxiety, PTSD, and brain injury. Their Othmer Method is among the most widely trained neurofeedback approaches globally.

Israeli biotechnology company developing novel psychedelic-inspired compounds derived from tryptamine chemistry for treatment-resistant depression and PTSD. They leverage Israel's strong neuropharmacology research infrastructure to advance their pipeline.

electroCore is a publicly traded bioelectronic medicine company focused on non-invasive vagus nerve stimulation (nVNS). Their gammaCore device is FDA-cleared for cluster headache and migraine prevention and has applications across neurology and inflammation.

Elemind has developed a closed-loop neurostimulation wearable that reads EEG signals in real time and delivers targeted acoustic stimulation to modulate brain states for sleep and focus. Their consumer-grade headband uses proprietary algorithms to synchronize stimulation with individual brainwave patterns.

Eleusis is a life sciences company developing psychedelic-based medicines, with a focus on LSD microdosing for Alzheimer's disease neuroinflammation and psilocybin for major depression. They combine neuroscience research with drug development.

EMOTIV produces consumer and research-grade EEG headsets that enable brain-computer interaction, mental wellness monitoring, and cognitive performance tracking. Their EPOC and MN8 devices are widely used in academic research, workplace wellness, and adaptive technology applications.

Australian clinical-stage biopharmaceutical company developing MDMA, psilocybin, and cannabis-derived therapeutics for mental health conditions with a data-driven clinical trial platform. They operate licensed clinics to generate real-world evidence for regulatory submissions.

Enspire Medical is developing an implantable sacral neuromodulation device for overactive bladder and bowel dysfunction, featuring wireless recharging and Bluetooth-enabled patient control.

AI-powered drug discovery company using machine learning to identify and develop novel psychedelic-derived compounds for mental health disorders. Their platform accelerates the identification of serotonergic candidates with therapeutic potential.

Entheon Biomedical is developing DMT-based therapies for addiction and substance use disorders, including alcohol and nicotine dependence. Their clinical programs aim to combine psychedelic-assisted therapy with structured psychological support.

Entorian Technologies develops ultra-miniaturized neural interface electronics and stacked-chip architectures enabling high-density wireless neural recording and stimulation for research and clinical neuroprosthetics applications.

Psychedelic-assisted therapy company operating clinics across North America offering ketamine therapy alongside proprietary digital tools for patient preparation and integration. They also conduct psilocybin research through their drug development subsidiary.

Filament Health is developing natural psychedelic drug candidates extracted from plants, including psilocybin mushrooms and iboga, for addiction and mental health treatment. Their botanical extraction approach differentiates them from synthetic psychedelic competitors.

Flow Neuroscience combines a CE-marked tDCS headset with a digital therapy app to treat major depression at home. Their closed-loop approach pairs brain stimulation with behavioral therapy sessions guided by a smartphone application.

Leading psychedelic therapy training organization offering continuing education for mental health professionals in ketamine and psychedelic-assisted psychotherapy. Their curriculum is accredited and widely adopted across North America.

GH Research is a clinical-stage biopharmaceutical company developing inhaled 5-MeO-DMT (GH001) as a rapid-acting treatment for treatment-resistant depression. Their proprietary inhalation delivery method is designed to produce predictable, short-duration psychedelic experiences.

GrayMatters Health developed Prism, an EEG-guided closed-loop neurofeedback digital therapeutic for PTSD that trains patients to self-regulate amygdala activity using real-time brain signals.

g.tec medical engineering is an Austrian company producing high-performance biosignal acquisition systems, BCI software, and neurostimulation equipment used in research hospitals and academic neuroscience labs worldwide. Their g.USBamp and g.Nautilus systems are gold standards in BCI and EEG research.

Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare and other neurological diseases, with Wakix (pitolisant) as its lead approved product for excessive daytime sleepiness in narcolepsy. Wakix is the first non-scheduled prescription medicine approved for narcolepsy in the United States.

Canadian psychedelic company focused on the development of standardized natural psilocybin extracts and psychedelic-assisted therapy protocols. Their work bridges traditional plant medicine with modern clinical research frameworks.

Headspace Health merged Headspace and Ginger to create a comprehensive mental health super-app offering meditation, coaching, and on-demand therapy. Their enterprise and health plan products are used by over 100 million people worldwide.

Hi-D Therapeutics is a Singapore-based CNS startup developing deuterium-stabilized analogues of existing neurological drugs to extend half-life and reduce metabolic toxicity in Parkinson's and Huntington's disease.

IDUN Technologies develops in-ear EEG electrodes embedded in earbud form factor devices for unobtrusive, long-term neural monitoring. Their dry contact ear electrodes enable continuous brainwave recording in everyday environments for health monitoring and BCI applications.

Ieso Digital Health is a UK-based company delivering internet-enabled cognitive behavioral therapy (iCBT) at scale through trained therapists and an AI-augmented clinical platform. They are a major provider to the NHS Talking Therapies program.

Telehealth platform providing ketamine-assisted therapy for depression, anxiety, and PTSD through a combination of at-home ketamine treatment and virtual psychotherapy. They offer an integrated care model with licensed prescribers and therapists.

Intan Technologies manufactures low-noise, high-channel-count neural recording chips and headstages used by academic and industrial neuroscience researchers globally. Their RHD and RHS series integrated circuits have become a standard in electrophysiology research systems.

InteraXon created the Muse headband, a consumer EEG device that provides real-time brain feedback during meditation and sleep to guide users toward calmer mental states. The Muse S and Muse 2 are among the best-selling consumer neurofeedback devices worldwide.

Intra-Cellular Therapies is a biopharmaceutical company focused on CNS disorders, best known for Caplyta (lumateperone), an FDA-approved treatment for schizophrenia and bipolar depression. Their drug discovery platform targets intracellular signaling pathways in neurons.

Bioventus Neurology offers non-invasive ultrasound-based neuromodulation platforms targeting musculoskeletal pain pathways and peripheral nerve conditions through focused therapeutic ultrasound.

US-based platform enabling licensed therapists to incorporate ketamine-assisted psychotherapy into their practices through a collaborative care model. They provide medical oversight, prescribing infrastructure, and clinical training.

Karuna Therapeutics developed KarXT (xanomeline-trospium), a novel muscarinic receptor-based treatment for schizophrenia that received FDA approval in 2024 under the brand name Cobenfy, representing the first new mechanism of action for schizophrenia in decades. Karuna was acquired by Bristol Myers Squibb in 2024 for approximately $14 billion.

Koa Health is a digital mental health company offering app-based interventions for anxiety, depression, and burnout delivered through employers and health systems. Their platform combines clinical content with AI-driven personalization.

Limbic is a UK-based AI mental health company that builds clinical-grade tools to support therapists and streamline access to psychological therapies. Their AI assessment and support product is integrated into NHS mental health services.

LivaNova is a global medical device and pharmaceutical company specializing in neuromodulation and cardiac surgery, best known for their vagus nerve stimulation (VNS) therapy for epilepsy and treatment-resistant depression. Their SenTiva VNS device offers personalized, automated therapy adjustments for patients with drug-resistant conditions.

Lumos Labs operates Lumosity, a brain training platform with games designed to challenge memory, attention, flexibility, and problem-solving skills. With over 100 million users, their platform also supports research on cognitive performance.

Formerly MAPS Public Benefit Corporation, Lykos Therapeutics is advancing MDMA-assisted therapy for PTSD through Phase 3 clinical trials and FDA regulatory review. They are a pioneer in the clinical development of psychedelic-assisted psychotherapy.

Lyra Health provides an employer-sponsored mental health platform connecting employees to evidence-based therapists, coaches, and mental health tools through a digital marketplace. Their Lyra Care model blends video therapy, digital programs, and medication management to support the full spectrum of mental health needs.

Magnus Medical developed SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), a personalized TMS protocol that uses fMRI-guided targeting to deliver rapid antidepressant effects. Their system received FDA Breakthrough Device designation and aims to compress weeks of TMS treatment into days.

Magstim is a leading manufacturer of transcranial magnetic stimulation equipment used in both clinical treatment and neuroscience research, including FDA-cleared TMS systems for major depressive disorder. They supply TMS devices to hospitals, clinics, and research institutions worldwide.

MAPS is a non-profit research and educational organization that has sponsored Phase 3 clinical trials of MDMA-assisted therapy for PTSD through its public benefit corporation subsidiary MAPS PBC. They have been the primary driver of bringing MDMA-assisted psychotherapy toward regulatory approval globally.

mBrainTrain develops portable, wireless EEG amplifiers optimized for mobile brain-body imaging and real-world neuroscience research. Their SMARTING system integrates seamlessly with standard EEG caps and streams data to mobile devices for ambulatory cognitive research.

Medtronic's Neuromodulation division is a global leader in deep brain stimulation (DBS), spinal cord stimulation, and targeted drug delivery for conditions including Parkinson's disease, essential tremor, chronic pain, and epilepsy. Their Percept PC DBS system with BrainSense technology enables real-time neural sensing during therapy delivery.

Mentalab produces the Explore system, a portable and wireless EEG device designed for mobile neuroscience research and BCI development outside the lab. Their open-source compatible hardware enables researchers to run experiments in naturalistic environments.

Meru Health is a digital clinic for depression, anxiety, and burnout that combines therapist-led coaching, biofeedback wearables, and an app-based program. Their 12-week program is clinically validated and covered by major US insurers.

Media, events, and intelligence platform dedicated to psychedelic medicine and business, providing industry news, investment data, and hosting leading global psychedelic conferences. They serve as a key information hub for the emerging psychedelic industry ecosystem.

Mind Alive designs and manufactures audio-visual entrainment and cranio-electro stimulation devices used for relaxation, sleep improvement, and cognitive enhancement. Their DAVID devices are used by practitioners and consumers for non-invasive brainwave entrainment and neurofeedback applications.

Australian non-profit leading efforts to establish regulatory pathways for psilocybin and MDMA-assisted therapies in Australia, successfully achieving landmark TGA rescheduling. They fund clinical research and therapist training programs nationally.

MindAffect develops a rapid, code-modulated visual evoked potential (c-VEP) BCI that enables non-verbal communication for people with ALS and locked-in syndrome. Their open-source platform achieves high information transfer rates using standard EEG headsets without training.

Mental health and wellness company delivering at-home ketamine therapy for depression and anxiety through telemedicine and guided digital experiences. They have treated tens of thousands of patients with a technology-enabled care model.

Digital health platform connecting patients with licensed practitioners for psychedelic integration therapy and mental wellness support. Their app facilitates pre- and post-session care to enhance the durability of psychedelic treatment outcomes.

MindSeaTech develops underwater and maritime human factors monitoring tools using EEG and physiological sensors for defense and research applications. Their wearable neural monitoring systems assess diver and operator cognitive states in extreme environments.

Mindstrong developed passive digital biomarkers derived from smartphone usage patterns to monitor mental health conditions like depression and bipolar disorder. Their platform was designed to support clinical care management for serious mental illness.

Mydecine Innovations is developing psilocybin-based therapies for PTSD and smoking cessation, with a digital therapy platform to support psychedelic treatment. They also have a biosynthesis program to produce novel psilocybin analogues.

myNEURVA provides a clinician-guided neurofeedback platform for cognitive rehabilitation targeting post-concussion syndrome and traumatic brain injury recovery. Their cloud-based system pairs patients with remote neurofeedback therapists.

Endonovo Therapeutics develops wearable pulsed electromagnetic field (PEMF) devices targeting neuroinflammation, delivering non-invasive neuromodulation for traumatic brain injury recovery and chronic pain.

Nalu Medical has created a micro-sized, rechargeable neurostimulation system for chronic pain that is dramatically smaller than conventional implantable pulse generators. Their Nalu Neurostimulation System enables flexible programming and remote care capabilities for patients with back and limb pain.

Natus Medical is a leading provider of neurology and newborn care medical devices, offering products for EEG, EMG, evoked potentials, and newborn hearing screening. Their Nicolet and Excel-Tech EEG systems are used in hospitals and neurology clinics across more than 100 countries.

Neeuro is a Singapore-based neurotechnology company that develops EEG-based cognitive training and monitoring platforms for healthcare and education. Their SenzeBand EEG headset and Memorie brain training app target cognitive health in aging populations and children with learning challenges.

Neuromod Devices is an Irish MedTech company that developed Lenire, a CE-marked bimodal neuromodulation device combining tongue and sound stimulation to treat chronic tinnitus.

Neumora Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to brain diseases, with a pipeline targeting depression, schizophrenia, and other psychiatric disorders through novel receptor-targeted mechanisms. Their lead asset navacaprant is a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder.

Neurable integrates passive BCI technology into consumer headphones to measure focus and cognitive state throughout the workday. Their MW75 Neuro headphones use dry EEG sensors to deliver personalized productivity insights without any additional hardware.

Neuracle Neuroscience develops clinical-grade wireless EEG monitoring systems for long-term ambulatory brain monitoring in epilepsy diagnosis, ICU care, and neurological disease management. Their NeuroCap disposable pre-gelled EEG cap dramatically reduces setup time and infection risk compared to traditional EEG electrode placement in clinical settings.

Neural Analytics developed the Lucid system, an AI-powered transcranial Doppler ultrasound device for automated brain health assessment at the bedside. Their technology enables non-invasive monitoring of cerebral blood flow dynamics to detect conditions like vasospasm and elevated intracranial pressure.

The BrainGate Consortium is a multi-institutional research collaboration between Brown University, Stanford, Case Western, and Massachusetts General Hospital pioneering intracortical BCI technology for restoring communication and motor function in paralysis. Their Utah array-based implants have enabled landmark demonstrations of cursor control, robotic arm use, and speech decoding in clinical trial participants.

Neuralace Medical is developing a minimally invasive subdural neurostimulation system for drug-resistant epilepsy and chronic pain applications. Their thin-film electrode arrays conform to the brain surface to deliver precise cortical stimulation through a less invasive surgical approach.

Neuracle Neuroscience is a Chinese neurotechnology company developing wireless EEG systems and BCI platforms for clinical and consumer applications. Their NeuSen W series wireless EEG headsets are used in hospitals and research institutions across Asia.

Neuralign has developed a digital platform that uses standardized neuropsychological assessments and EEG biomarkers to identify and treat reading and learning disabilities in children. Their Lokomat-compatible neurofeedback and cognitive training tools are deployed in schools and clinics.

Synchron's Australian operations and clinical trial hub developed the Stentrode, a minimally invasive endovascular BCI implanted via a blood vessel without open brain surgery. Their device has enabled ALS patients to control computers and smartphones through motor imagery.

Neuraltus Pharmaceuticals is developing NP001, a novel immunomodulatory therapy targeting neuroinflammation in ALS patients by reprogramming inflammatory macrophages and microglia.

NeuraVi is an Australian neuromodulation startup developing closed-loop vagus nerve stimulation devices targeting treatment-resistant depression and inflammatory disorders.

Neuroadaptive Technologies develops passive BCI systems that use real-time EEG to infer cognitive states and adapt machine behavior accordingly without explicit user input. Their research focuses on workload monitoring and human-automation teaming for aerospace and defense applications.

Neurobiological Technologies is a CNS pharmaceutical company that developed NeuroBiological Technologies (NBT) platform for neuroprotective peptide therapies targeting acute neurological injury and neurodegeneration.

Neurogene is a gene therapy company developing NGN-101, an AAV-based treatment for CLN5 Batten disease, using a proprietary EXACT technology platform to regulate transgene expression in the CNS.

Neuroelectrics designs wireless, high-density EEG and transcranial electrical stimulation systems for research and clinical neuromodulation. Their Starstim platform enables simultaneous multi-channel tCS and EEG recording in a single wearable headset.

NeuroEne Therapeutics is an Israeli startup developing endocannabinoid-based CNS modulators for treatment-resistant epilepsy and neuropathic pain, leveraging proprietary lipid nanoparticle delivery technology.

Neurolutions developed the IpsiHand Upper Extremity Rehabilitation System, a BCI-powered exoskeleton that helps stroke survivors regain hand and arm function. The device received FDA Breakthrough Device designation and is used in clinical stroke rehabilitation settings.

Neuromed is an Italian medical device company specializing in implantable spinal cord stimulation and deep brain stimulation systems for chronic pain and movement disorders. Their Ares DBS and SCS platforms are distributed across European clinical centers.

Neurona Therapeutics is developing NRTX-1001, a one-time cell therapy using human interneurons derived from stem cells to treat drug-resistant focal epilepsy through targeted circuit modulation.

NeuroPhos Therapeutics is a Swedish clinical-stage company developing phospholipid-based nanoparticle drug delivery systems to enhance CNS bioavailability of neurological therapeutics.

Specialty pharmaceutical company developing intranasal delivery formulations of psychedelic compounds including psilocybin and ketamine for rapid onset psychiatric treatment. Their proprietary nasal delivery technology improves bioavailability and dose precision.

Neuronetics is a publicly traded medical device company that markets the NeuroStar Advanced Therapy System, an FDA-cleared TMS platform for major depressive disorder and obsessive-compulsive disorder. Their system has treated over 100,000 patients across thousands of clinical practices in the US.

NeuroPace developed the RNS System, the first and only FDA-approved closed-loop neurostimulation device for drug-resistant epilepsy that detects and responds to abnormal brain activity in real time. The implantable device continuously monitors neural signals and delivers targeted stimulation to prevent seizures before they start.

NeurOptimal, developed by Zengar Institute, offers a dynamical neurofeedback system that trains the brain using real-time EEG feedback without targeting specific brainwave states. Their system is used by clinicians and consumers worldwide for stress, sleep, and performance optimization.

Cala Health develops wrist-worn peripheral nerve stimulation therapy (Cala Trio) for essential tremor, delivering individualized transcutaneous stimulation calibrated to each patient's tremor frequency.

Neuros Medical is developing the HFAC (High-Frequency Alternating Current) Nerve Block technology to treat chronic post-amputation pain through a minimally invasive implantable device that blocks pain signals at the peripheral nerve. Their Altius system has received FDA Breakthrough Device Designation and targets one of the most undertreated pain conditions in veterans and amputees.

Neurosity builds the Crown, a developer-focused EEG headset designed for building productivity and focus applications using brain-computer interface APIs. Their platform allows software developers to create apps that respond to mental states like focus, calm, and cognitive load in real time.

Neurotrack has developed an eye-tracking cognitive assessment tool that detects early signs of Alzheimer's disease and cognitive decline using a standard webcam. Their digital platform supports both clinical research and consumer brain health monitoring.

Nevro is a publicly traded medical device company offering the HFX spinal cord stimulation platform delivering 10 kHz high-frequency therapy for chronic back and leg pain without paresthesia.

Nevro is a publicly traded medical device company specializing in spinal cord stimulation therapy for chronic pain, best known for its HF10 high-frequency SCS platform that operates at 10 kHz to reduce paresthesia. Their devices are FDA-approved for treating intractable back and leg pain.

Nexstim is a Finnish medical technology company specializing in navigated brain stimulation, offering the NBS System for neurosurgical planning and the NBT System for treating major depressive disorder with TMS. Their proprietary eXimia technology provides precise, image-guided transcranial magnetic stimulation.

Nihon Kohden is a major Japanese medical electronics company producing a comprehensive range of EEG, EMG, and polysomnography systems used globally in clinical neurology and sleep medicine. Their monitoring platforms are known for precision signal quality and are trusted in ICU and epilepsy monitoring units worldwide.

Impact investment fund dedicated to supporting psychedelic science, therapy access, and policy reform through philanthropic and mission-aligned capital. They fund research institutions, advocacy organizations, and clinical programs globally.

Novamind operates ketamine-assisted therapy clinics and conducts psychedelic clinical research across the United States and Canada. Their network of Cedar Psychiatry and Novamind clinics integrates evidence-based psychedelic treatments with psychiatric care.

Psychedelic-assisted therapy training and retreat organization providing evidence-based programs integrating mystical experience frameworks with clinical practice. They focus on therapist education and patient preparation protocols.

Digital mental health company offering at-home ketamine therapy combined with proprietary digital integration programs and health coaching. Their platform uses data science to personalize treatment and track outcomes longitudinally.

Numinus Wellness is a Canadian publicly listed mental health company operating clinics that offer ketamine-assisted therapy and psychedelic-assisted psychotherapy, while also running a Health Canada-licensed facility for psychedelic research and compound production. They bridge clinical care and drug development in the psychedelic medicine space.

Nurokor is an Australian medtech company developing bioelectronic neuromodulation devices that use targeted electrical stimulation to improve athletic performance and rehabilitation outcomes. Their wearable technology is used by elite sports teams globally.

Nuvectra was a publicly traded neurostimulation company that developed the Algovita spinal cord stimulation system for chronic pain management. The company also had DBS and sacral neuromodulation platforms under development before ceasing operations.

Israeli neurotechnology company developing non-invasive closed-loop brain stimulation devices that adapt in real-time to neural biomarkers for treating psychiatric and neurological disorders. Their platform integrates EEG monitoring with transcranial stimulation to personalize therapy.

Open Ephys is a nonprofit organization that develops open-source hardware and software for extracellular electrophysiology research. Their Open Ephys GUI and acquisition board are widely adopted in academic neuroscience labs for high-channel neural recording.

OpenBCI makes open-source brain-computer interface hardware and software, including the Cyton, Ganglion, and Ultracortex headsets, designed to democratize access to EEG and biopotential sensing for researchers, developers, and makers. Their open ecosystem has fostered a broad community of BCI innovation worldwide.

Osmind provides an EHR and practice management platform specifically designed for psychiatric providers offering innovative treatments like ketamine, TMS, and esketamine (Spravato). Their software streamlines patient intake, outcome tracking, and billing for cutting-edge mental health clinics.

Paradromics is developing a high-bandwidth neural data transmission system using large arrays of microwire electrodes to enable high-fidelity brain-computer interfaces for patients with severe paralysis. Their Argo BCI system is designed for clinical restoration of communication.

Perception Neuroscience is developing arketamine (R-ketamine) as a rapid-acting antidepressant with a potentially more favorable side-effect profile than esketamine. Their program targets treatment-resistant depression and suicidal ideation.

Supernus Pharmaceuticals is a CNS-focused specialty pharmaceutical company commercializing Oxtellar XR and Trokendi XR for epilepsy, and Qelbree for ADHD, with an active neuropsychiatry pipeline.

Persyst develops AI-powered EEG analysis software that automates spike detection, seizure identification, and quantitative EEG analysis to assist neurologists in reading complex EEG recordings more efficiently. Their Persyst 14 platform integrates with major EEG hardware vendors and is used in clinical and research settings.

Philips Neuro, a division of Royal Philips, offers a comprehensive portfolio of EEG systems, long-term monitoring solutions, and diagnostic neurology software used in hospital neurology departments and ICUs worldwide. Their Alice and Natus-integrated platforms support epilepsy monitoring, sleep studies, and intraoperative neuromonitoring.

Photopharmics develops the Celeste light therapy device, a precisely calibrated intrinsically photosensitive retinal ganglion cell (ipRGC) stimulator designed to treat Parkinson's disease non-motor symptoms.

San Francisco-based clinical center specializing in ketamine-assisted psychotherapy and training mental health professionals in psychedelic-assisted treatment modalities. They integrate depth psychology with emerging psychedelic medicine practices.

Posit Science develops BrainHQ, a suite of evidence-based brain training exercises targeting processing speed, memory, and attention validated in over 100 peer-reviewed studies. Their platform is used by healthcare systems, employers, and consumers to improve cognitive function.

Precision Neuroscience develops a minimally invasive brain-computer interface using a thin-film electrode array called the Layer 7 Cortical Interface, designed for rapid surgical placement on the brain's surface. Their technology aims to restore communication and motor function in patients with paralysis.

Biotechnology company developing next-generation psychedelic-derived therapeutics targeting neurological and psychiatric disorders. They focus on novel analogs of psilocybin and DMT with improved pharmacological profiles.

Leading psychedelic industry research and intelligence platform tracking clinical trials, regulatory developments, and company news across the global psychedelic medicine space. They provide data-driven insights for investors and researchers.

Digital mental health company building AI-powered tools to personalize and monitor psychedelic-assisted therapy sessions and patient outcomes. Their platform supports therapists with real-time biometric and psychological state tracking.

Neurotechnology company developing EEG-based biomarkers and digital cognitive assessments to predict and monitor response to psychedelic-assisted therapies. Their platform provides objective neurological metrics to support clinical decision-making.

Psych360 is a mental health technology company focused on expanding access to ketamine-assisted therapy and psychedelic-informed psychiatric care through a network of outpatient clinics and digital health tools. They aim to bridge the gap between emerging psychedelic science and accessible, evidence-based outpatient psychiatric treatment.

Quartet Health is a tech-enabled mental health platform that connects patients with the right behavioral health care through health system partnerships. Their technology identifies patients in need and coordinates care between physical and mental health providers.

Reata Pharmaceuticals developed omaveloxolone (Skyclarys), the first FDA-approved treatment for Friedreich's ataxia, acting as an Nrf2 activator to reduce oxidative stress in neuronal mitochondria.

Reunion Neuroscience is developing RE104, a novel psychedelic compound with a shorter duration of action than psilocybin, targeting postpartum depression and major depressive disorder. Their approach aims to improve practicality of psychedelic-assisted therapy.

Canadian specialty pharmaceutical company advancing psilocybin and cannabidiol-based therapeutics for rare diseases and mental health conditions. Their lead program targets treatment-resistant PTSD with psilocybin-assisted therapy.

Ripple Neuro develops high-channel-count neural interface systems for intraoperative and chronic recording applications. Their Grapevine neural interface processor is widely used in clinical and research BCIs worldwide.

Rune Labs builds software infrastructure for neural data, enabling clinicians and researchers to leverage data from implanted neurostimulators like Medtronic's Percept. Their StrivePD platform integrates neural biomarkers with wearable data to optimize Parkinson's treatment.

Sage Therapeutics is a biopharmaceutical company pioneering GABA and NMDA receptor-targeted medicines for brain health disorders, with Zurzuvae (zuranolone) being the first once-daily oral pill FDA-approved for postpartum depression. They continue to advance a pipeline targeting major depressive disorder, epilepsy, and essential tremor.

Saluda Medical has developed the world's first closed-loop spinal cord stimulation system, the Evoke SCS, which automatically adjusts stimulation in real time by sensing the spinal cord's response. This feedback-driven approach improves therapy consistency and patient outcomes in chronic pain.

SC Neuro is a Canadian neurostimulation company developing non-invasive spinal cord stimulation devices for restoring upper and lower limb function in patients with spinal cord injury.

Seelos Biosciences is a clinical-stage company developing intranasal racemic ketamine (SLS-002) for acute suicidal ideation and behavior in major depressive disorder. They have a broader pipeline targeting CNS and rare disease indications.

SetPoint Medical develops an implantable bioelectronic medicine device that stimulates the vagus nerve to treat inflammatory diseases including rheumatoid arthritis and Crohn's disease.

Neuros Medical develops the HALO system, a high-frequency nerve block neurostimulator designed to treat post-amputation phantom limb pain by non-destructively silencing peripheral nerve activity.

Psychedelic wellness company operating legal psilocybin mushroom retreats in Jamaica and developing metered-dose functional mushroom products. They focus on making psychedelic experiences accessible under legal jurisdictions.

SilverCloud Health provides digital mental health and wellbeing programs based on CBT, delivered to patients through health systems and employers. Acquired by Amwell, their platform serves millions of users across Ireland, the UK, and North America.

Small Pharma is a clinical-stage psychedelic medicine company developing short-duration DMT-assisted therapy for major depressive disorder. Their lead program SPL026 has completed Phase IIa trials in the UK.

Soterix Medical manufactures transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) devices for research and clinical applications. Their HD-tDCS systems enable high-definition, focal non-invasive brain stimulation widely used in academic neuroscience.

Spark Neuro develops targeted electrical neurostimulation for neurological and psychiatric conditions, with a lead program in sphenopalatine ganglion stimulation for cluster headache and major depression.

Spinal Modulation pioneered dorsal root ganglion (DRG) stimulation therapy for localized chronic pain, developing the Axium Neurostimulator System acquired by St. Jude Medical.

Spring Health is an employer-focused mental health benefits platform that uses machine learning to personalize mental health care, matching employees to the right level of care including therapy, coaching, and medication management. They have become one of the most well-funded mental health startups in the US.

Stimwave develops wireless, minimally invasive neurostimulation devices for chronic pain management, featuring the world's smallest spinal cord stimulator powered by external radio frequency energy.

Supernus Pharmaceuticals is a specialty CNS biopharmaceutical company with a portfolio of approved products for epilepsy, ADHD, and Parkinson's disease, including Oxtellar XR, Trokendi XR, Qelbree, and Gocovri. They focus on developing differentiated medicines for underserved neurological conditions.

Synapse Biomedical developed the NeuRx Diaphragm Pacing System, an FDA-approved implantable neurostimulator that electrically conditions the diaphragm to restore breathing in ALS and spinal cord injury patients.

Netherlands-based legal psilocybin retreat and training organization offering psychedelic-assisted therapy programs for professionals and individuals. They also train facilitators through accredited certification programs.

Drug discovery company developing entactogen-based medicines derived from MDMA analogs for psychiatric conditions including PTSD and social anxiety. Their pipeline focuses on compounds with refined safety and efficacy profiles.

Canadian non-profit advocacy organization that secured the first legal psilocybin therapy exemptions in Canada and supports patient access to psilocybin for end-of-life distress. They also provide therapist training and regulatory guidance.

Thought Technology is a Canadian company manufacturing multi-modal biofeedback and neurofeedback instruments used in clinical, research, and performance settings. Their ProComp and FlexComp systems measure EEG, EMG, HRV, and other physiological signals for therapeutic training.

TMS Health Solutions operates a network of outpatient TMS therapy clinics across the United States, providing transcranial magnetic stimulation treatment for major depressive disorder and OCD.

Translatum Medicus is a Greek biopharmaceutical startup developing novel adenosine receptor modulators and neuroinflammation inhibitors for Parkinson's disease and Huntington's disease.

Tryp Therapeutics is developing psilocybin-based therapies for eating disorders, fibromyalgia-associated depression, and other conditions with high unmet need. They focus on specific patient populations where psychedelic-assisted therapy may offer significant benefit.

Two Chairs is a mental health clinic combining therapist matching technology with in-person and virtual therapy services across the United States. Their data-driven matching platform aims to improve therapy outcomes and reduce dropout rates.

Usona Institute is a nonprofit medical research organization conducting Phase 3 clinical trials of psilocybin for major depressive disorder. As a mission-driven organization, they aim to develop psilocybin as an accessible, non-proprietary medicine.

Neurexo Biosciences is a German spin-out developing exosome-based RNA therapeutics for acute CNS injuries including stroke and traumatic brain injury, leveraging engineered extracellular vesicles for BBB penetration.

UK-based company developing AI-driven therapeutic music tools designed to support psychedelic-assisted therapy sessions. Their platform personalizes sound environments to optimize patient emotional states during treatment.

Wesana Health is a psychedelic medicine company focused on developing psilocybin-based treatments for traumatic brain injury and associated mental health conditions. They are building a pipeline targeting neurological damage and PTSD.

Woebot Health develops an AI-powered mental health chatbot that delivers cognitive behavioral therapy (CBT) techniques through conversational interfaces. Their flagship product helps users manage anxiety, depression, and stress in real time.

Wysa is an AI-powered emotional wellbeing app that uses evidence-based CBT, DBT, and mindfulness techniques delivered via a conversational chatbot. It is used by millions globally and has partnerships with healthcare systems in the UK and India.

Zai Lab is a China-based biopharmaceutical company with a growing CNS pipeline including partnered assets for major depressive disorder, schizophrenia, and Parkinson's disease targeting Asian patient populations.